Next Article in Journal
The Anticancer Activity Conferred by the Mud Crab Antimicrobial Peptide Scyreprocin through Apoptosis and Membrane Disruption
Previous Article in Journal
Impaired LEF1 Activation Accelerates iPSC-Derived Keratinocytes Differentiation in Hutchinson-Gilford Progeria Syndrome
Previous Article in Special Issue
A Wide-Proteome Analysis to Identify Molecular Pathways Involved in Kidney Response to High-Fat Diet in Mice
Article

Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes

Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 8b Street, 20-090 Lublin, Poland
*
Author to whom correspondence should be addressed.
Academic Editors: Galliera Emanuela Rita and Elena Vianello
Int. J. Mol. Sci. 2022, 23(10), 5502; https://doi.org/10.3390/ijms23105502
Received: 1 April 2022 / Revised: 9 May 2022 / Accepted: 11 May 2022 / Published: 14 May 2022
(This article belongs to the Special Issue New Molecular Mechanisms and Markers in Inflammatory Disorders)
Many relevant studies, as well as clinical practice, confirm that untreated diabetes predisposes the development of neuroinflammation and cognitive impairment. Having regard for the fact that PPARγ are widely distributed in the brain and PPARγ ligands may regulate the inflammatory process, the anti-inflammatory potential of the PPARγ agonist, pioglitazone, was assessed in a mouse model of neuroinflammation related with diabetes. In this regard, the biochemical and molecular indicators of neuroinflammation were determined in the hippocampus and prefrontal cortex of diabetes mice. The levels of cytokines (IL-1β, IL-6, and TNF) and the expression of genes (Tnfrsf1a and Cav1) were measured. In addition, behavioral tests such as the open field test, the hole-board test, and the novel object recognition test were conducted. A 14-day treatment with pioglitazone significantly decreased IL-6 and TNFα levels in the prefrontal cortex and led to the downregulation of Tnfrsf1a expression and the upregulation of Cav1 expression in both brain regions of diabetic mice. Pioglitazone, by targeting neuroinflammatory signaling, improved memory and exploratory activity in behavioral tests. The present study provided a potential theoretical basis and therapeutic target for the treatment of neuroinflammation associated with diabetes. Pioglitazone may provide a promising therapeutic strategy in diabetes patients with muffled of behavioral activity. View Full-Text
Keywords: neuroinflammation; diabetes; pioglitazone; anti-inflammatory effect; exploratory behaviors; memory neuroinflammation; diabetes; pioglitazone; anti-inflammatory effect; exploratory behaviors; memory
Show Figures

Figure 1

MDPI and ACS Style

Piątkowska-Chmiel, I.; Herbet, M.; Gawrońska-Grzywacz, M.; Dudka, J. Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes. Int. J. Mol. Sci. 2022, 23, 5502. https://doi.org/10.3390/ijms23105502

AMA Style

Piątkowska-Chmiel I, Herbet M, Gawrońska-Grzywacz M, Dudka J. Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes. International Journal of Molecular Sciences. 2022; 23(10):5502. https://doi.org/10.3390/ijms23105502

Chicago/Turabian Style

Piątkowska-Chmiel, Iwona, Mariola Herbet, Monika Gawrońska-Grzywacz, and Jarosław Dudka. 2022. "Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes" International Journal of Molecular Sciences 23, no. 10: 5502. https://doi.org/10.3390/ijms23105502

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop